The Novel Suspension Quail Cell Line CCX.E10 Is an Ideal Cell Substrate for Newcastle Disease Virus (NDV) and Vector Production
Newcastle disease is a highly infectious viral disease of the avian species. The causative agent is Newcastle disease virus (NDV), which belongs to the family of Paramyxoviridae. Many commercial vaccines, both live and inactivated, are available on the market and protect from NDV infection and disease.
In addition, viral vectors based on Newcastle disease virus have been previously evaluated as vaccines against e.g. Sars-CoV-2, Ebola, H5N1 influenza, West Nile, and Simian Immunodeficiency virus. Also, oncolytic Newcastle disease viruses and vectors are seen as a promising immunotherapeutic strategy against various cancers.
Avian Cell Lines for Human and Veterinary Vaccine Manufacturing
Currently, many NDV-based vaccines and viral vectors are still produced using a traditional process in embryonated chicken eggs or primary chicken embryo fibroblasts (CEF).
However, CEFs are not ideal for state-of-the-art vaccine production as it requires specific-pathogen-free (SPF) embryonated eggs in large numbers to generate a primary cell culture. Such technologies are not considered robust manufacturing systems as they are highly susceptible to microbial contamination and are highly variable with respect to yield and quality due to the heterogeneity of the starting material (embryonated eggs).
Therefore avian cell lines, have become a modern option for human and veterinary vaccine manufacturing and can replace egg and primary fibroblast technology. Such examples are the DF-1, AGE1, QOR and EB66 cell lines, used for the development and production of vaccines.
Nuvonis Novel Suspension Avian Cell Line CCX.E10
The recently introduced novel suspension avian cell line CCX.E10 established by Nuvonis offers R&D and GMP cell banks various advantages over the existing avian cell lines: CCX.E10 was developed without the use of foreign genes or viral sequences and is therefore considered a non-GMO cell substrate. The CCX.E10 cell line grows in suspension but can also be obtained as anchorage-dependent version for companies utilizing existing production infrastructure (e.g. roller bottles, cell factories and microcarrier culture). The cell line grows in a serum-free / animal component-free medium that is commercially available.
CCX.E10 allows to obtain high-virus titers when infected with Newcastle disease virus (NDV). Nuvonis demonstrated that NDV can be grown to 8-9 log/ml TCID50/FFA at low multiplicity of infection and within 24-48 hours. This illustrates the potential of the new CCX.E10 cell line as a platform technology for a broad range of NDV products in the human and veterinary fields.
Nuvonis is eager to supply research organisations, start-ups, vaccine manufacturers and CMOs working on the development of NDV-based therapies. Nuvonis offers R&D and GMP cell banks (MCB and/or WCB) that are fully characterised according to ICH guidelines and can be used in a GMP setting without any delay.